Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer

Trial Profile

Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary) ; Paclitaxel
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms OCTOVA
  • Most Recent Events

    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 14 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top